Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion (NASDAQ: ESPR) announced the acceptance of four presentations at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. The presentations include one featured presentation in the Late Breaker/Featured Science track focusing on bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease from the CLEAR Outcomes Trial. Additionally, three poster presentations will cover liver steatosis and cardiovascular events, statin intolerance effects on patient management, and real-world effectiveness of bempedoic acid plus ezetimibe therapy.
Esperion (NASDAQ: ESPR) has announced it will report its third quarter 2024 financial results on Thursday, November 7, 2024, before market opens. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. A live audio webcast will be accessible through Esperion's website, with the replay available for approximately 90 days after the call. The company focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol treatment.
Esperion announced final 2-year follow-up data from the German cohort of the MILOS study, evaluating real-world use of bempedoic acid in patients with primary hypercholesterolemia or mixed dyslipidemia. The study showed:
- A 30.3% average relative reduction in LDL-C levels from pre-treatment to 2 years
- An increase in patients reaching LDL-C goals from 4.9% to 35.3% at 2-year follow-up
- Over 80% of patients received bempedoic acid with other lipid-lowering therapies
- Safety profile consistent with the CLEAR clinical trial program
The data demonstrates the effectiveness of bempedoic acid in real-world settings, supporting its role in helping patients achieve LDL-C goals and potentially reducing cardiovascular event risks.
Esperion (NASDAQ: ESPR) announced on September 25, 2024, that it granted 3,500 restricted stock units (RSUs) to a new employee on September 23, 2024, under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for granting equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment, in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest as follows: 25% on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET. The event will be webcasted live and accessible through Esperion's investor and media website section. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a company focused on discovering, developing, and commercializing innovative medicines for patients with or at risk of cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next steps in LDL-cholesterol reduction.
Esperion announced expanded coverage for NEXLETOL® and NEXLIZET®, their FDA-approved non-statin medications for lowering LDL cholesterol and reducing cardiovascular risk. The drugs now have access to over 92% of commercially insured lives and 65% of Medicare lives, totaling more than 170 million covered individuals. This increased coverage follows the FDA's approval of expanded indications for both primary and secondary prevention patients.
The improved formulary status and streamlined prior authorization processes make it easier for healthcare providers to prescribe these medications. NEXLETOL and NEXLIZET are unique in being the only non-statins FDA-approved for both LDL-C reduction and cardiovascular risk reduction in patients unable to take recommended statin therapy.
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET. The event will be webcasted live and accessible through the investor and media section of Esperion's website. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a pharmaceutical company focused on developing innovative medicines for cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next-step solutions in reducing LDL-cholesterol levels. The company emphasizes the importance of lowering cholesterol levels as much as possible, as quickly as possible.
Esperion (NASDAQ: ESPR) reported strong Q2 2024 financial results, with total revenue increasing 186% year-over-year to $73.8 million. U.S. net product revenue grew 39% to $28.3 million, driven by a 14% increase in total retail prescription equivalents from Q1. The company completed a transformational transaction, monetizing European royalties for $304.7 million and using the proceeds to pay off and terminate the Oberland Capital Revenue Interest Facility.
Key highlights include:
- Expanded payer coverage, with over 80% of payers updating utilization management criteria
- Increased preferred commercial coverage to 92% and Medicare preferred coverage to over 50%
- Received a five-year patent extension for bempedoic acid through December 3, 2030
- Achieved significant international progress, including label expansion approval in Europe and positive Phase 3 results in Japan
Esperion (NASDAQ: ESPR) announced on August 7, 2024, the granting of 66,800 restricted stock units (RSUs) to 18 new employees under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment.
The RSUs will vest over four years, with 25% vesting on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% vesting in twelve equal quarterly installments thereafter. Vesting is subject to continued employment with Esperion. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) has announced it will report its second quarter 2024 financial results on Monday, August 12, 2024, before the market opens. Following the release, the company will host a webcast at 8:00 a.m. ET to discuss the financial results and provide business updates. Investors can pre-register for the conference call to obtain dial-in information, and a live audio webcast will be accessible on Esperion's website. The webcast replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is focused on discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases. The company aims to help patients with high cholesterol reach their LDL-cholesterol reduction goals.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
